His Bundle Pacing and Left Bundle Branch Pacing in Patients with Heart Failure
Patrycja Paluszkiewicz1, Adrian Martuszewski2, Jadwiga Radziejewska3
1Department of Emergency Medical Service, Wroclaw Medical University, ul. Parkowa 34, 51-616 Wrocław, Poland.
Biomedicines
|October 26, 2024
Summary
His bundle pacing (HBP) and left bundle branch pacing (LBBP) offer improved cardiac function and outcomes for heart failure patients compared to conventional pacing. These advanced techniques restore physiological conduction with fewer complications.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- His bundle pacing (HBP) and left bundle branch pacing (LBBP) are novel pacing strategies for heart failure and conduction disorders.
- These techniques aim to restore natural cardiac conduction, potentially improving heart function over traditional methods.
Purpose of the Study:
- To evaluate the efficacy and safety of HBP and LBBP.
- Compare these advanced pacing methods against conventional pacing in patients with heart failure and conduction disturbances.
Main Methods:
- A comprehensive review of recent studies and clinical trials was performed.
- Analysis focused on cardiac function, QRS duration, patient outcomes, clinical efficacy, procedural safety, and long-term benefits.
Main Results:
- Both HBP and LBBP demonstrated significant improvements in cardiac function and clinical outcomes versus conventional pacing.
- HBP restored physiological conduction, reducing QRS duration; LBBP enhanced left ventricular activation.
- Both techniques showed lower complication rates and higher success in achieving optimal pacing thresholds.
Conclusions:
- HBP and LBBP represent promising alternatives to traditional pacing for specific patient groups.
- These advanced strategies offer superior outcomes and improved cardiac function with reduced risks.
- Further research is necessary to confirm long-term benefits and safety across diverse populations.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
527
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
527
01:22Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
01:29Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure VI: Adjunct Therapies
1
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
1
01:30Heart Failure IV: Classification and Diagnostic Evaluation
1
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1